In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo
- PMID: 38437690
- DOI: 10.7326/J24-0008
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo
Abstract
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232. 37952131.
Conflict of interest statement
Comment on
-
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical